Biochemical and functional characteristics of human epididymis protein 4 (HE4);Caratteristiche biochimiche e funzionali della proteina 4 dell'epididimo umano (HE4)

Biochimica Clinica

Volumn 38, Issue 5, 2014, Pages 368-373

  Schiumarini, Domitilla ^a   Ferraro, Simona ^a   Panteghini, Mauro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HUMAN EPIDIDYMIS PROTEIN 4; PROTEIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; WFDC2 PROTEIN;

CANCER GROWTH; EXON; METASTASIS; NEOPLASM; OVARY CANCER; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SPERMATOZOON MATURATION;

EID: 84907166870     PISSN: 03930564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. AIRTUM Working Group. Italian cancer figures, report 2011: Survival of cancer patients in Italy. Epidemiol Prev 2011;35:1-200.
2. Sandri MT, Bottari F, Franchi D. "Recognition and initial management of ovarian cancer": un'analisi commentata del documento preparato dal National Institute of Health and Clinical Excellence (NICE). Biochim Clin 2013;37:220-8.
3. Sturgeon CM, Duffy MJ, Stenman U-H, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79.
4. Gion M, Trevisiol C, Pregno S, et al. a nome dei Gruppi e Comitati di Progetto della Guida. Guida all'uso clinico dei biomarcatori in oncologia: i marcatori nelle diverse neoplasie - Parte II. Biochim Clin 2011;35:465-73.
5. th ed. Philadelphia, PA: Mosby Elsevier, 2007:313-67.
6. Bast Jr RC. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003;21:200s-5s.
7. Bandiera E, Romani C, Specchia C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev 2011;20:2496-506.
8. Ferraro S, Braga F, Lanzoni M, et al. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J. Clin Pathol 2013;66:273-81.
9. Klug TL, Bast RC, Niloff JM, et al. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA125) associated with human epithelial ovarian carcinomas. Cancer Res 1984;44:1048-53.
10. Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod 1998;3:86-95.
11. Bouchard D, Morisset D, Bourbannais Y, et al. Proteins with whey-acidic protein motifs and cancer. Lancet Oncol 2006;7:167-74.
12. Li J, Dowdy S, Tipton T, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009;9:555-66.
13. Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitor. Biol Reprod 1991;45:350-7.
14. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 2002;368:233-42.
15. Bingle L, Singleton V, Bingle CD. The putative ovarian tumor marker gene HE4 (WFDC2) is expressed in normal tissue and undergoes alternative splicing to yield multiple protein isoform. Oncogene 2002;21:2768-73.
16. Clauss A, Lilja H, Lundwall A. The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun 2005;333:383-9.
17. Drapkin R, von Horsten HH, Lin Y. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-9.
18. Bingle L, Cross SS, High AS, et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 2006;7:61.
19. Galgano MT, Hampton GM, Frierson Jr HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-53.
20. Zou SL, Chang XH, Ye X, et al. Effect of human epididymis protein 4 gene silencing on the malignant phenotype in ovarian cancer. Clin Med J 2011;124:3133-40.
21. Gao L, Cheng HY, Dong L, et al. The role of HE4 in ovarian cancer: inhibiting tumour cell proliferation and metastasis. J Int Med Res 2011;39:1645-60.
22. Chhikara N, Saraswat M, Tomar AK, et al. Human epididymis protein 4 (HE4): A novel cross-class protease inhibitor. PLoS One 2012;7:47672-84.
23. Lu R, Sun X, Xiao R, et al. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun 2012;419:274-80.
24. Hertlein L, Stieber P, Kirschenhofer A, et al. Human epididymis protein 4 (HE4) in benign e malignant disease. Clin Chem Lab Med 2012;50:2181-8.
25. Jiang SW, Chen H, Dowdy S, et al. HE4 transcription and splice variant specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci 2013;14:22655-77.
26. Zhu XY, Gao GL, Tang SB, et al. Effect of WFDC2 silencing on the proliferation, motility and invasion of human serous ovarian cancer cell in vitro. Asian Pac J Trop Med 2013;6:265-72.
27. Chen Y, Mu X, Wang S, et al. WAP four disulfide core domain protein 2 mediates the proliferation of human ovarian cancer cells through the regulation of growth and apoptosis-associated gene. Oncol Rep 2013;29:288-96.
28. Moore RG, Hill EK, Horan T, et al. HE4 (WFDC2) gene overexpression promotes ovarian tumour growth. Sci Rep 2014;4:3574-81.